Sulfatinib T capsule + Sulfatinib R capsule
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relative Bioavailability
Conditions
Relative Bioavailability
Trial Timeline
Apr 2, 2018 → May 18, 2018
NCT ID
NCT03483259About Sulfatinib T capsule + Sulfatinib R capsule
Sulfatinib T capsule + Sulfatinib R capsule is a phase 1 stage product being developed by HUTCHMED for Relative Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT03483259. Target conditions include Relative Bioavailability.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03483259 | Phase 1 | Completed |
Competing Products
6 competing products in Relative Bioavailability
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab + Sonelokimab | MoonLake Immunotherapeutics | Phase 1 | 28 |
| ABT-333 | AbbVie | Phase 1 | 33 |
| BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg | AstraZeneca | Phase 1 | 33 |
| D1400147 + D14000136 + D14000137 + Epanova® | AstraZeneca | Phase 1 | 33 |
| Ropivacaine 0.1% + Ropivacaine 0.4% | Baxter | Approved | 82 |
| Tebipenem tablet form | Spero Therapeutics | Phase 1 | 25 |